Search

Your search keyword '"Horn, Biljana N."' showing total 39 results
Start Over Author "Horn, Biljana N."
39 results on '"Horn, Biljana N."'

1. A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients

Author

Drusbosky, Leylah M., Singh, Neeraj Kumar, Hawkins, Kimberly E., Salan, Cesia, Turcotte, Madeleine, Wise, Elizabeth A., Meacham, Amy, Vijay, Vindhya, Anderson, Glenda G., Kim, Charlie C., Radhakrishnan, Saumya, Ullal, Yashaswini, Talawdekar, Anay, Sikora, Huzaifa, Nair, Prashant, Khanna-Gupta, Arati, Abbasi, Taher, Vali, Shireen, Guha, Subharup, Farhadfar, Nosha, Murthy, Hemant S., Horn, Biljana N., Leather, Helen L., Castillo, Paul, Tucker, Caitlin, Cline, Christina, Pettiford, Leslie, Lamba, Jatinder K., Moreb, Jan S., Brown, Randy A., Norkin, Maxim, Hiemenz, John W., Hsu, Jack W., Slayton, William B., Wingard, John R., and Cogle, Christopher R.

Published
2019
Full Text
View/download PDF

2. A trial of alemtuzumab adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency.

Author

Dvorak, Christopher C, Horn, Biljana N, Puck, Jennifer M, Adams, Stuart, Veys, Paul, Czechowicz, Agnieszka, and Cowan, Morton J

Subjects
Humans, Severe Combined Immunodeficiency, Histocompatibility Testing, Treatment Outcome, Transplantation Conditioning, Chemotherapy, Adjuvant, Hematopoietic Stem Cell Transplantation, Transplantation, Homologous, Prospective Studies, Pilot Projects, Child, Infant, California, Male, Antibodies, Monoclonal, Humanized, Alemtuzumab, alemtuzumab, engraftment, haploidentical, severe combined immunodeficiency, Engraftment, Haploidentical, Severe combined immunodeficiency, Chemotherapy, Adjuvant, Transplantation, Homologous, Antibodies, Monoclonal, Humanized, Surgery, Paediatrics and Reproductive Medicine
Abstract

For infants with SCID the ideal conditioning regimen before allogeneic HCT would omit cytotoxic chemotherapy to minimize short- and long-term complications. We performed a prospective pilot trial with alemtuzumab monotherapy to overcome NK-cell mediated immunologic barriers to engraftment. We enrolled four patients who received CD34-selected haploidentical cells, two of whom failed to engraft donor T cells. The two patients who engrafted had delayed T-cell reconstitution, despite rapid clearance of circulating alemtuzumab. Although well-tolerated, alemtuzumab failed to overcome immunologic barriers to donor engraftment. Furthermore, alemtuzumab may slow T-cell development in patients with SCID in the setting of a T-cell depleted graft.

Published
2014

3. A trial of plerixafor adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency.

Author

Dvorak, Christopher C, Horn, Biljana N, Puck, Jennifer M, Czechowicz, Agnieszka, Shizuru, Judy A, Ko, Rose M, and Cowan, Morton J

Subjects
Humans, Severe Combined Immunodeficiency, Heterocyclic Compounds, Granulocyte Colony-Stimulating Factor, Histocompatibility Testing, Treatment Outcome, Hematopoietic Stem Cell Mobilization, Transplantation Conditioning, Combined Modality Therapy, Chemotherapy, Adjuvant, Drug Therapy, Combination, Hematopoietic Stem Cell Transplantation, Prospective Studies, Pilot Projects, Adolescent, Child, Infant, California, Female, Male, engraftment, haploidentical, plerixafor, severe combined immunodeficiency, Engraftment, Haploidentical, Plerixafor, Severe combined immunodeficiency, Chemotherapy, Adjuvant, Drug Therapy, Combination, Stem Cell Research, Clinical Research, Cancer, Pediatric, Hematology, Regenerative Medicine, Stem Cell Research - Nonembryonic - Human, Transplantation, Surgery, Paediatrics and Reproductive Medicine
Abstract

For infants with SCID, the ideal conditioning regimen before allogeneic HCT would omit cytotoxic chemotherapy to minimize short- and long-term complications. We performed a prospective pilot trial with G-CSF plus plerixafor given to the host to mobilize HSC from their niches. We enrolled six patients who received CD34-selected haploidentical cells and one who received T-replete matched unrelated BM. All patients receiving G-CSF and plerixafor had generally poor CD34(+) cell and Lin(-) CD34(+) CD38(-) CD90(+) CD45RA(-) HSC mobilization, and developed donor T cells, but no donor myeloid or B-cell engraftment. Although well tolerated, G-CSF plus plerixafor alone failed to overcome physical barriers to donor engraftment.

Published
2014

4. SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID

Author

Schuetz, Catharina, Neven, Benedicte, Dvorak, Christopher C, Leroy, Sandrine, Ege, Markus J, Pannicke, Ulrich, Schwarz, Klaus, Schulz, Ansgar S, Hoenig, Manfred, Sparber-Sauer, Monika, Gatz, Susanne A, Denzer, Christian, Blanche, Stephane, Moshous, Despina, Picard, Capucine, Horn, Biljana N, de Villartay, Jean-Pierre, Cavazzana, Marina, Debatin, Klaus-Michael, Friedrich, Wilhelm, Fischer, Alain, and Cowan, Morton J

Subjects
Cancer, Transplantation, Genetics, Rare Diseases, Orphan Drug, Hematology, Aetiology, 2.1 Biological and endogenous factors, B-Lymphocytes, DNA-Binding Proteins, Endonucleases, Female, Follow-Up Studies, Graft vs Host Disease, HLA Antigens, Hematopoietic Stem Cell Transplantation, Homeodomain Proteins, Humans, Lymphocyte Depletion, Male, Mutation, Nuclear Proteins, Risk Factors, Severe Combined Immunodeficiency, T-Lymphocytes, Transplantation Conditioning, Treatment Outcome, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Paediatrics and Reproductive Medicine, Immunology
Abstract

A subgroup of severe combined immunodeficiencies (SCID) is characterized by lack of T and B cells and is caused by defects in genes required for T- and B-cell receptor gene rearrangement. Several of these genes are also involved in nonhomologous end joining of DNA double-strand break repair, the largest subgroup consisting of patients with T(-)B(-)NK(+)SCID due to DCLRE1C/ARTEMIS defects. We postulated that in patients with ARTEMIS deficiency, early and late complications following hematopoietic cell transplantation might be more prominent compared with patients with T(-)B(-)NK(+)SCID caused by recombination activating gene 1/2 (RAG1/2) deficiencies. We analyzed 69 patients with ARTEMIS and 76 patients with RAG1/2 deficiencies who received transplants from either HLA-identical donors without conditioning or from HLA-nonidentical donors without or with conditioning. There was no difference in survival or in the incidence or severity of acute graft-versus-host disease regardless of exposure to alkylating agents. Secondary malignancies were not observed. Immune reconstitution was comparable in both groups, however, ARTEMIS-deficient patients had a significantly higher occurrence of infections in long-term follow-up. There is a highly significant association between poor growth in ARTEMIS deficiency and use of alkylating agents. Furthermore, abnormalities in dental development and endocrine late effects were associated with alkylation therapy in ARTEMIS deficiency.

Published
2014

5. Hematopoietic Cell Transplant and Use of Massage for Improved Symptom Management: Results from a Pilot Randomized Control Trial

Author

Mehling, Wolf E, Lown, E Anne, Dvorak, Christopher C, Cowan, Morton J, Horn, Biljana N, Dunn, Elizabeth A, Acree, Michael, Abrams, Donald I, and Hecht, Frederick M

Subjects
Biomedical and Clinical Sciences, Health Services and Systems, Nursing, Clinical Sciences, Health Sciences, Clinical Research, Cancer, Pediatric, Stem Cell Research, Behavioral and Social Science, Prevention, Mind and Body, Transplantation, Clinical Trials and Supportive Activities, Regenerative Medicine, Mental Health, Chronic Pain, Pain Research, Evaluation of treatments and therapeutic interventions, 6.6 Psychological and behavioural, Complementary and Alternative Medicine, Complementary & Alternative Medicine, Pharmacology and pharmaceutical sciences, Traditional, complementary and integrative medicine
Abstract

Background. Pediatric hematopoietic cell transplant (HCT) is a lifesaving treatment that often results in physical and psychological discomfort. An acupressure-massage intervention may improve symptom management in this setting. Methods. This randomized controlled pilot trial compared a combined massage-acupressure intervention to usual care. Children were offered three practitioner-provided sessions per week throughout hospitalization. Parents were trained to provide additional acupressure as needed. Symptoms were assessed using nurses' reports and two questionnaires, the behavioral affective and somatic experiences scale and the Peds quality of life cancer module. Results. We enrolled 23 children, ages 5 to 18. Children receiving the intervention reported fewer days of mucositis (Hedges' g effect size ES = 0.63), lower overall symptom burden (ES = 0.26), feeling less tired and run-down (ES = 0.86), having fewer moderate/severe symptoms of pain, nausea, and fatigue (ES = 0.62), and less pain (ES = 0.42). The intervention group showed trends toward increasing contentness/serenity (ES = +0.50) and decreasing depression (ES = -0.45), but not decreased anxiety (ES = +0.42). Differences were not statistically significant. Discussion. Feasibility of studying massage-acupressure was established in children undergoing HCT. Larger studies are needed to test the efficacy of such interventions in reducing HCT-associated symptoms in children.

Published
2012

6. Early Donor T-Cell Engraftment Is Critical for Immune Tolerance in Reduced Intensity Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)

Author

Connelly, Jim A., primary, Biltibo, Eden, additional, Wilkerson, Karina, additional, Seber, Adriana, additional, Gouveia, Roseane V, additional, Bonfim, Carmem, additional, Simões, Belinda Pinto, additional, Nur, Erfan, additional, Horn, Biljana N., additional, Eckrich, Michael, additional, Hanna, Rabi, additional, Dhedin, Nathalie, additional, Almhareb, Fahed, additional, Aljurf, Mahmoud, additional, Rangarajan, Hemalatha G., additional, Gatwood, Katie S., additional, Orton, Lindsay, additional, Kitko, Carrie Lynn, additional, Alzahrani, Mohsen, additional, Alahmari, Ali Debsan, additional, De La Fuente, Josu, additional, and Kassim, Adetola A., additional

Published
2022
Full Text
View/download PDF

7. Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)

Author

Kassim, Adetola A., primary, Wilkerson, Karina, additional, de la Fuente, Josu, additional, Seber, Adriana, additional, Gouveia, Roseane V, additional, Bonfim, Carmem, additional, Simões, Belinda Pinto, additional, Nur, Erfan, additional, Horn, Biljana N., additional, Eckrich, Michael, additional, Hanna, Rabi, additional, Dhedin, Nathalie, additional, Almhareb, Fahed, additional, Aljurf, Mahmoud, additional, Rangarajan, Hemalatha G., additional, Gatwood, Katie S., additional, Connelly, James P, additional, Alzahrani, Mohsen, additional, Alahmari, Ali, additional, Rodeghier, Mark, additional, and DeBaun, Michael R., additional

Published
2022
Full Text
View/download PDF

13. CAR2.0 Therapy for the Management of Post-Transplantation Relapse of B-Cell Acute Lymphoblastic Leukemia

Author

Zhang, Rui, primary, Xiao, Juan, additional, Liu, Zhouyang, additional, Sun, Yuan, additional, Tu, Sanfang, additional, Li, Yuhua, additional, Zhang, Leping, additional, Cheng, Yifei, additional, Xue, Song, additional, Zhang, Yongping, additional, Wang, Kai, additional, Wang, Bin, additional, Zheng, Huyong, additional, Nishio, Nobuhiro, additional, Takahashi, Yoshiyuki, additional, Feng, Jia, additional, Xu, Haichan, additional, Liu, Yuchen, additional, Li, Yuchen, additional, Jiao, Cheng, additional, Horn, Biljana N., additional, and Chang, Lung-Ji, additional

Published
2020
Full Text
View/download PDF

14. Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Severe Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)

Author

Kassim, Adetola A., primary, de la Fuente, Josu, additional, Alahmari, Ali Debsan, additional, Eckrich, Michael J., additional, Hanna, Rabi, additional, Dhedin, Nathalie, additional, Horn, Biljana N., additional, Black, Vandy, additional, Gouveia, Roseane V, additional, Seber, Adriana, additional, Simões, Belinda Pinto, additional, Costa, Thalita Cristina de Mello, additional, Guerino-Cunha, Renato, additional, Bonfim, Carmem M. S., additional, da Silva, Roberto Luiz, additional, Hamerschlak, Nelson, additional, Fernandes, Juliana Folloni, additional, Kent, Michael, additional, Yadav, Satya Prakash, additional, Nur, Erfan, additional, Alzahrani, Mohsen, additional, Carpenter, Ben, additional, Tse, William, additional, Isabel, Maria, additional, Rangarajan, Hemalatha G, additional, Ahmed, Ibrahim, additional, Akinsete, Adeseye Michael, additional, Fitzhugh, Courtney D., additional, Culos, Kathryn A., additional, Karnik, Leena, additional, Connelly, James, additional, Kitko, Carrie, additional, Andrews, Jennifer, additional, Wilkerson, Karina L, additional, Brodsky, Robert, additional, Koyama, Tatsuki, additional, and DeBaun, Michael R., additional

Published
2020
Full Text
View/download PDF

18. Abstract 3253: Droplet digital PCR is a sensitive method for detecting refractory acute myeloid leukemia (AML) clones in peripheral blood and saliva

Author

Hawkins, Kimberly E., primary, Salan, Cesia, additional, Turcotte, Madeleine, additional, Vaughn, Lauren T., additional, Zhang, Mei, additional, Zhang, Yanping, additional, Sawicki, Barry, additional, Anderson, Glenda G., additional, Farhadfar, Nosha, additional, Murthy, Hemant S., additional, Horn, Biljana N., additional, Leather, Helen L., additional, Castillo, Paul, additional, Norkin, Maxim, additional, Hiemenz, John W., additional, Brown, Randy A., additional, Slayton, William, additional, Hsu, Jack W., additional, Wingard, John R., additional, Cogle, Christopher R., additional, and Drusbosky, Leylah M., additional

Published
2018
Full Text
View/download PDF

21. Icare 1: A Prospective Clinical Trial to Predict Treatment Response Based on Mutanome-Informed Computational Biology in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Author

Drusbosky, Leylah M., Hawkins, Kimberly E., Salan, Cesia, Turcotte, Madeleine, Anderson, Glenda G., Singh, Neeraj Kumar, Radhakrishnan, Saumya, Ullal, Yashaswini, Talawdekar, Anay, Sikora, Huzaifa, Nair, Prashant, Bhowmick, Priyanka, Abbasi, Taher, Vali, Shireen, Zou, Fei, Farhadfar, Nosha, Murthy, Hemant S., Horn, Biljana N., Leather, Helen L., Castillo, Paul, Sawicki, Barry, Brown, Randy A., Norkin, Maxim, Hiemenz, John W., Hsu, Jack W., Slayton, William, Wingard, John R., and Cogle, Christopher R.

Published
2017
Full Text
View/download PDF

22. Digital Drug Screening and Computational Modeling Identifies Treatment Opportunities Despite Lack of Directly Actionable Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Author

Drusbosky, Leylah M., Hawkins, Kimberly E., Turcotte, Madeleine, Murthy, Hemant S., Leather, Helen L., Farhadfar, Nosha, Norkin, Maxim, Wingard, John R., Hiemenz, John W., Castillo, Paul, Brown, Randy A., Slayton, William, Horn, Biljana N., Vasista, Sumanth, Basu, Kabya, Usmani, Shahabuddin, Roy, Kunal Ghosh, Lala, Deepak Anil, Radhakrishnan, Saumya, Kumar, Rajeev, Rajagopalan, Swaminathan, Abbasi, Taher, Vali, Shireen, and Cogle, Christopher R.

Published
2017
Full Text
View/download PDF

23. A Genomic Signature Predicting Venetoclax Treatment Response in Acute Myeloid Leukemia (AML) Identified By Protein Network Mapping and Validated By Ex Vivo Ddrug Sensitivity Testing

Author

Drusbosky, Leylah M., Hawkins, Kimberly E., Leather, Helen L., Murthy, Hemant S., Farhadfar, Nosha, Wingard, John R., Norkin, Maxim, Brown, Randy A., Hiemenz, John W., Castillo, Paul, Horn, Biljana N., Kumar, Ansu, Singh, Neeraj Kumar, Kumar, Chandan, Vasista, Sumanth, Abbasi, Taher, Vali, Shireen, Tognon, Cristina E., Kurtz, Stephen E, Druker, Brian J., Tyner, Jeffrey W., Pollyea, Daniel A., and Cogle, Christopher R.

Published
2017
Full Text
View/download PDF

26. Allogeneic Hematopoietic Cell Transplantation for Fanconi Anemia in Patients With Pretransplantation Cytogenetic Abnormalities, Myelodysplastic Syndrome, or Acute Leukemia

Author

Ayas, Mouhab, primary, Saber, Wael, additional, Davies, Stella M., additional, Harris, Richard E., additional, Hale, Gregory A., additional, Socie, Gerard, additional, LeRademacher, Jennifer, additional, Thakar, Monica, additional, Deeg, H. Joachim J., additional, Al-Seraihy, Amal, additional, Battiwalla, Minoo, additional, Camitta, Bruce M., additional, Olsson, Richard, additional, Bajwa, Rajinder S., additional, Bonfim, Carmem M., additional, Pasquini, Ricardo, additional, MacMillan, Margaret L., additional, George, Biju, additional, Copelan, Edward A., additional, Wirk, Baldeep, additional, Al Jefri, Abdullah, additional, Fasth, Anders L., additional, Guinan, Eva C., additional, Horn, Biljana N., additional, Lewis, Victor A., additional, Slavin, Shimon, additional, Stepensky, Polina, additional, Bierings, Marc, additional, and Gale, Robert Peter, additional

Published
2013
Full Text
View/download PDF

29. Is There a Role for ASCT in Patients with Desmoplastic Small Round Cell Tumor of the Peritoneum?

Author

Cook, Rachel J, primary, Wang, Zhiwei, additional, Arora, Mukta, additional, Lazarus, Hillard M., additional, Kasow, Kimberly A., additional, Champagne, Martin A., additional, Saber, Wael, additional, Van Besien, Koen M., additional, Hale, Gregory A., additional, Copelan, Edward A., additional, Elmongy, Mohamed, additional, Ueno, Naoto T, additional, Horn, Biljana N., additional, Slavin, Shimon, additional, and Stadtmauer, Edward A., additional

Published
2011
Full Text
View/download PDF

31. Allogeneic Hematopoietic Cell Transplantation (HCT) for Neuroblastoma (NB): The CIBMTR Experience

Author

Hale, Gregory A., primary, Grupp, Stephan A, additional, Kasow, Kimberly A., additional, Bishop, Michael R., additional, Bitan, Menachem, additional, Childs, Richard, additional, Copelan, Edward A., additional, Cairo, Mitchell S., additional, Camitta, Bruce, additional, Chan, Ka Wah, additional, Davies, Stella M., additional, Diaz, Miguel A., additional, Doyle, John J, additional, Gale, Robert Peter, additional, Gonzalez, Vicent M., additional, Horn, Biljana N., additional, Jodele, Sonata, additional, Kamani, Naynesh R., additional, Lazarus, Hillard M., additional, Lewis, Victor A., additional, Myers, Kasiani C., additional, Pulsipher, Michael A., additional, Qayed, Muna, additional, Sanders, Jean, additional, Shaw, Peter J., additional, Soni, Sandeep, additional, Stadtmauer, Edward A., additional, Stiff, Patrick, additional, Wall, Donna A., additional, and Arora, Mukta, additional

Published
2011
Full Text
View/download PDF

34. Results Of The Large Prospective Study On The Use Of Defibrotide (DF) In The Treatment Of Hepatic Veno-Occlusive Disease (VOD) In Hematopoietic Stem Cell Transplant (HSCT). Early Intervention Improves Outcome - Updated Results Of a Treatment IND (T-IND) Expanded Access Protocol

Author

Richardson, Paul G., Smith, Angela R., Triplett, Brandon M., Kernan, Nancy A., Grupp, Stephan A, Arai, Sally, Haut, Paul R., Martin, Paul L., Symons, Heather J., Lehmann, Leslie E., Simms-Waldrip, Tiffany, Gillio, Alfred P., III, Horn, Biljana N., Shore, Tsiporah B., Krishnan, Amrita Y., Petrovic, Aleksandra, Kirov, Ivan I., Woolfrey, Ann E., Greiner, Robert J., Mineishi, Shin, Boyer, Michael, Hannah, Alison L., Antin, Joseph H., Hume, Robin, Bandiera, Valeria, Heringa, Carin, and Soiffer, Robert J.

Published
2013
Full Text
View/download PDF

35. Results of a Large Prospective Study On the Use of Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Hematopoietic Stem Cell Transplant (HSCT). Early Intervention Improves Outcome – Updated Results of a Treatment IND (T-IND) Expanded Access Protocol

Author

Richardson, Paul G., Smith, Angela, Kernan, Nancy A., Grupp, Stephan A., Arai, Sally, Triplett, Brandon M., Haut, Paul R., Chan, Kawah, Symons, Heather J., Horn, Biljana N., Gillio, Alfred P., III, Boyer, Michael, Krishnan, Amrita, Lehmann, Leslie E., Martin, Paul L., Mineishi, Shin, Shore, Tsiporah B., Simms-Waldrip, Tiffany, Antin, Joseph H., Hannah, Alison L., Hume, Robin, Tudone, Elena, Heringa, Carin, and Soiffer, Robert J.

Published
2012
Full Text
View/download PDF

36. Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Stem Cell Transplant (SCT) and Non-SCT Patients (Pts): Early Intervention Improves Outcome - Updated Results of a Treatment IND Expanded Access Protocol

Author

Richardson, Paul G., Smith, Angela R., Grupp, Stephan A, Kernan, Nancy A., Arai, Sally, Haut, Paul R., Triplett, Brandon M., Gillio, Alfred P., III, Symons, Heather J., Adams, Roberta H., Horn, Biljana N., Lucas, Kenneth, Martin, Paul L., Mineishi, Shin, Ball, Edward D., Boyer, Michael, Fort, John, Kirov, Ivan I., Lehmann, Leslie E., Madigan, Catherine, Maglio, Michelle E., Massaro, Joseph, D'Agostino, Ralph B., Hannah, Alison L., Tudone, Elena, Hume, Robin, Iacobelli, Massimo, and Soiffer, Robert J.

Published
2011
Full Text
View/download PDF

37. Defibrotide (DF) in the treatment of hepatic veno-occlusive disease (VOD) in stem cell transplant (SCT) and non-SCT patients (Pts): Early intervention improves outcome - Updated results of a treatment IND expanded access protocol

Author

Richardson, Paul G., Smith, Angela R., Grupp, Stephan A., Kernan, Nancy A., Arai, Sally, Haut, Paul R., Brandon Triplett, Gillio, Alfred P., Symons, Heather J., Adams, Roberta H., Horn, Biljana N., Lucas, Kenneth, Martin, Paul L., Mineishi, Shin, Ball, Edward D., Boyer, Michael, Fort, John, Kirov, Ivan I., Lehmann, Leslie E., Madigan, Catherine, Maglio, Michelle E., Massaro, Joseph, D Agostino, Ralph B., Hannah, Alison L., Tudone, Elena, Hume, Robin, Iacobelli, Massimo, Soiffer, Robert J., and Defibrotide Study Grp

38. A Genomic Signature Predicting Venetoclax Treatment Response in Acute Myeloid Leukemia (AML) Identified By Protein Network Mapping and Validated By Ex VivoDdrug Sensitivity Testing

Author

Drusbosky, Leylah M., Hawkins, Kimberly E., Leather, Helen L., Murthy, Hemant S., Farhadfar, Nosha, Wingard, John R., Norkin, Maxim, Brown, Randy A., Hiemenz, John W., Castillo, Paul, Horn, Biljana N., Kumar, Ansu, Singh, Neeraj Kumar, Kumar, Chandan, Vasista, Sumanth, Abbasi, Taher, Vali, Shireen, Tognon, Cristina E., Kurtz, Stephen E, Druker, Brian J., Tyner, Jeffrey W., Pollyea, Daniel A., and Cogle, Christopher R.

Abstract

Data from a phase II clinical trial of venetoclax in AML recently supported its FDA breakthrough therapy designation for use in combination with hypomethylating agents in untreated AML patients ineligible for standard induction chemotherapy. Venetoclax is currently FDA approved for use in chronic lymphoid leukemia (CLL) patients with a 17(p) deletion who have been treated with at least 1 prior therapy. Del17(p) leads to loss of the TP53gene, encoding the key tumor suppressor p53. Loss of p53 results in BCL-2 overexpression, providing a target for venetoclax's mechanism of action. Approval of this BCL-2 inhibitor in CLL raises the question of mechanism of action in AML and patient selection for treatment. Unfortunately, no biomarkers or methods exist to predict venetoclax response in AML, making treatment selection challenging.

Published
2017
Full Text
View/download PDF

39. Massage Benefits Pediatric Transplant Patients.

Author

Ackerman, Sara L., Lown, E. Anne, Dvorak, Christopher C., Dunn, Elizabeth A., Abrams, Donald I., Horn, Biljana N., Degelman, Marcia, Cowan, Morton J., and Mehling, Wolf E.

Subjects
STEM cell transplantation, MASSAGE therapy, HEALTH outcome assessment, TREATMENT effectiveness, CHILDREN
Abstract

The article discusses the benefits that massage therapy provides for pediatric patients that are undergoing hematopoietic cell transplantation (HCT). Some of these include relief from pain and nausea, increased relaxation and ease in falling asleep. The findings of the study "Massage for Children Undergoing Hematopoietic Cell Transplantation: A Qualitative Report," are described. Parents were also instructed on how to give the massage that resulted in intimacy between patients and their parents.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results